DDA Liposome Pulmonary Vaccine: Preliminary Evaluation Data

Zhifa Xia's research article presents preliminary evaluation data for a dimethyldioctadecyl ammonium (DDA) cationic liposome-based pulmonary mucosal vaccine platform carrying a SARS-CoV-2 spike-derived branched peptide. The dataset, last updated in May 2026, is a 5.6 MB PDF containing results from in vitro dendritic cell activation tests and a mouse pulmonary mucosal immune model.

Use Cases

• Benchmarking nanoparticle vaccine formulations based on reported particle size and zeta potential.
• Analyzing immune response activation based on reported dendritic cell maturation and antibody levels.
• Studying vaccine retention and distribution based on reported lung and lymph node detection data.

Strengths

• Reported specific nanoparticle characteristics: uniform particle size (~101 nm), positive zeta potential (+42.67 mV), and high encapsulation efficiency (>80%).
• Includes results from a systematic evaluation using both in vitro and in vivo models.
• Released under a permissive CC-BY-4.0 license.

Limitations

• Description metadata is limited; actual data quality requires manual inspection after download.
• Column-level documentation is absent; field semantics must be inferred from the PDF.
• Row count is unknown, which may limit suitability assessment.

Provenance

Source

Zhifa Xia via figshare.

Collection Method

Data generated from laboratory experiments evaluating a novel vaccine formulation.

Freshness

Last updated 2026-05-29 06:07:31; freshness should be verified.